CompletedPhase 2NCT01295944
Carboplatin and Bevacizumab for Recurrent Ependymoma
Studying Anaplastic ependymoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Kevin Camphausen, M.D.National Cancer Institute (NCI)
- Intervention
- Carboplatin(drug)
- Enrollment
- 35 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2011 – 2021
Study locations (2)
- Massachusetts General Hospital/Dana Farber, Boston, Massachusetts, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01295944 on ClinicalTrials.govOther trials for Anaplastic ependymoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT05278208Lutathera for Treatment of Recurrent or Progressive High-Grade CNS TumorsNationwide Children's Hospital
- RECRUITINGNANCT05057702Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and EpendymomaUniversity of California, San Francisco
- RECRUITINGPHASE1NCT03750513LET Optimized IMPT in Treating Pediatric Patients With EpendymomaM.D. Anderson Cancer Center